Plant-based Vaccines Market Accrues Phenomenally by 2026 with Key Players Medicago, Inc., iBio, Inc., and Icon Genetics- GmbH.

Plant-based vaccines are increasingly being studied as a cheap alternative to the conventional vaccine in terms of efficiency, production time, and immune system. Plant-based vaccines market includes few market player and increasing number of start-up and research institutes, which are focused on R&D activities to develop treatment therapies for various infectious disease indications such as flu, dengue, norovirus, and avian influenza H5N1; based on new plant-based source vaccine.

For instance, in August 2018, researchers from Arizona State University’s (ASU) Biodesign Institute, developed a norovirus vaccine from tobacco plant. Genetic engineering has allowed researchers to transfer specific genes from tobacco plant in designing plant-based vaccine for norovirus. Plant-based vaccine safe and effective for use against various infectious diseases as it activates patient’s immune system.

Get Free Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2004

In June 2018, researchers from the University of Nottingham, Malaysia, announced a project to develop plant-based vaccine for treatment of dengue fever, caused by Aedes genus mosquitoes. The researchers produced vaccine antigen within the tobacco plant, which can neutralize dengue virus. Moreover, utilization of plant source in virus production offers new platform to provide vaccine that can be taken orally, as currently available vaccines are mostly given intravenously.

Key players in the global plant-based vaccines market are focused on in-organic growth strategies such as strategic collaborations and acquisition to harness R&D capabilities in development of new plant-based vaccines.

For instance, in June 2016, The Texas A&M University System (including Texas A & M University AgriLife Research and the Texas A & M Institute of Infectious Animal Diseases (IIAD)), entered into agreement with iBio, Inc., and its subsidiary, iBio CMO LLC for a collaborative program in plant-produced pharmaceuticals. The collaboration is expected to leverage R&D resources of the research institute with the commercial therapeutics and vaccine development and manufacturing capabilities of iBio. The goal of the collaboration is to rapidly develop and test cost-effective, commercial, therapeutic, and vaccine solutions against various diseases such as influenza and Ebola.

Furthermore, in July 2013, Medicago, Inc., a Canada-based biopharmaceutical company, entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation, whereby Medicago was acquired by Mitsubishi with 60% share in Medicago, Inc. 40% of the shares are currently held by Philip Morris Investments B.V.

Request TOC of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/2004

Detailed Segmentation:

Global Plant-based Vaccines Market, By Vaccine Type:
Bacterial Vaccines
Viral Vaccines
Parasite Vaccines
Others Vaccines
Global Plant-based Vaccines Market, By Source:
Tobacco Plant
Maize
Potato
Others Sources
Global Plant-based Vaccines Market, By Application:
Influenza
Zika Virus Disease
Ebola Virus Disease
Poultry Diseases
Others Applications

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.